Thursday, January 21, 2021

Decipher Biosciences Files For $100M IPO

San Diego-based Decipher Biosciences, a provider of genomic testing for urological cancer, has filed for an IPO, saying it is looking to raise up to $100M in an offering on the Nasdaq Global Market. The IPO is being underwritten by Evercore ISI, Wells Fargo Securities, Canaccord Genuity, and BTIG. The company has received funding from Yonghua International, CRG Partners, Tekla Capital, and UnitedHealth Group. The company has applied to list as DECI on the Nasdaq Global Market.